Penumbra SG&A Expenses 2014-2024 | PEN

Penumbra sg&a expenses for the twelve months ending December 31, 2024 were $0.574B, a 13.33% increase year-over-year.

  • Penumbra annual sg&a expenses for 2024 were $0.574B, a 13.33% increase from 2023.
  • Penumbra annual sg&a expenses for 2023 were $0.506B, a 12.62% increase from 2022.
  • Penumbra annual sg&a expenses for 2022 were $0.45B, a 18.87% increase from 2021.

Penumbra SG&A Expenses 2014-2024 | PEN

  • Penumbra annual sg&a expenses for 2024 were $0.574B, a 13.33% increase from 2023.
  • Penumbra annual sg&a expenses for 2023 were $0.506B, a 12.62% increase from 2022.
  • Penumbra annual sg&a expenses for 2022 were $0.45B, a 18.87% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$216B
Thermo Fisher Scientific (TMO)$205.7B
Alcon (ALC)$44.2B
Edwards Lifesciences (EW)$44.1B
IDEXX Laboratories (IDXX)$37.1B
DexCom (DXCM)$34.9B
IQVIA Holdings (IQV)$34.2B
Mettler-Toledo (MTD)$27.3B
Waters (WAT)$22.6B
STERIS (STE)$21.7B
SONOVA HOLDING (SONVY)$19.3B
Hologic (HOLX)$14.4B
Fresenius Medical Care AG KGaA (FMS)$13.5B
Sysmex ADR (SSMXY)$11.5B
Globus Medical (GMED)$11.5B
Masimo (MASI)$9.5B
Glaukos (GKOS)$8.7B
Teleflex (TFX)$8.1B
Inari Medical (NARI)$4.7B
Integer Holdings (ITGR)$4.5B
PROCEPT BioRobotics (PRCT)$3.4B
Veracyte (VCYT)$3.2B
Nihon Kohden (NHNKY)$2.7B
LivaNova (LIVN)$2.6B
TransMedics (TMDX)$2.5B
Elekta AB (EKTAY)$2.3B
Tandem Diabetes Care (TNDM)$2.1B
Integra LifeSciences Holdings (IART)$1.7B
Alphatec Holdings (ATEC)$1.5B
Pulse Biosciences (PLSE)$1.2B